VitroGel 3D-RGD

Grouped product items
SizePrice Qty
3mL + 50mL Dilution Solution Type 1
$585.00
3mL + 50mL Dilution Solution Type 2
$585.00
Catalog Number : V3DR

description

VitroGel is a ready-to-use, xeno-free tunable hydrogel system which closely mimics the natural extracellular matrix (ECM) environment.

VitroGel creates a functional and optimized environment to make cells feel like at home. The hydrogel system is room temperature stable, has a neutral pH, transparent, permeable and compatible with different imaging systems. The solution transforms into a tunable hydrogel matrix by simply mixing with cell culture medium. Cells cultured in this system can be easily harvested out with our VitroGel Cell Recovery Solution. The hydrogel can also be tuned to be injectable for in vivo studies.

From 2D coating, 3D culture to animal injection, VitroGel makes it possible to bridge the in vitro and in vivo studies with the same platform system.

VitroGel 3D-RGD is a ready-to-use tunable hydrogel system modified with RGD cell adhesive peptide, promoting the cell attachment and cell-matrix interactions during the 3D cell culture. This RGD modified hydrogel system is good for adhesion cells or cells need good cell-matrix interactions.

Review the Product Brochure for more details. 

Additional Information

Applications:
Cell Culture
Research Interest:Stem Cell Research
Cell Type:Stem Cells
Application:Cell Culture
Application Notes:
Formulation:
References:

Powell K. Adding depth to cell culture. Science. American Association for the Advancement of Science; 2017;356: 96–98.

Mahauad-Fernandez WD, Okeoma CM. B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells. Sci Rep. Nature Publishing Group; 2018;8: 4305. 

Mahauad-Fernandez WD, Naushad W, Panzner TD, Bashir A, Lal G, Okeoma CM. BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep. Nature Publishing Group; 2018;8: 17608. 

Li X, Seebacher NA, Xiao T, Hornicek FJ, Duan Z. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. J Orthop Res. 2019;37: 510–521. 

Hangzhan M, Nicole AS, Francis JH, Zhenfeng D. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019;39: 182-193. 

Seungwoo S, Jihye K, Je-Ryung L, Eun-chae J, Tae-Jin J, Wonhee L, YongKeun P. Enhancement of optical resolution in three-dimensional refractive-index tomograms of biological samples by employing micromirror-embedded coverslips. Lap Chip. 2018;18: 3484. 

© BioGems International, Inc. All rights reserved.